Ferozsons Laboratories Limited · PSX:FEROZ
Ferozsons Laboratories — Investor Presentation (November 2025)
22 slides from Ferozsons Laboratories's investor presentation, Nov 21, 2025
Slide 1: Corporate Briefing Session
CORPORATE BRIEFING SESSION FRIDAY, NOVEMBER 21, 2025 PEOPLE TRUST US
Slide 2: Agenda
AGENDA 1. Company Profile 2 Collaborations and Product Portfolio 3 Pharmaceutical Industry Highlights 4 Financial Performance 5 Questions and Answers Session P PEOPLE TRUST US
Slide 3: Company Information
COMPANY INFORMATION Incorporation Enlistment Principle Business Patient - Centricity First Pakistani Primarily Engaged We, being a Patient Incorporated in Pharmaceutical Co. in the Manufacture, Centric Company, 1954 as Listed on Stock Imports and Sale of take Pride in Private Limited Exchange in 196
Slide 4: Trustworthiness, Collaboration, Excellence
Trustworthiness Collaboration Excellence PEOPLE TRUST US
Slide 5: Corporate Structure
CORPORATE STRUCTURE Ferozsons Laboratories Limited BF Biosciences Ltd - Farmacia Subsidiary Company Retail Venture – 57.36% Holding 98% Partnership Interest PEOPLE TRUST US
Slide 6: Manufacturing Capabilities
MANUFACTURING CAPABILITIES cGMP Compliant Manufacturing Facilities: We have two cGMP compliant manufacturing facilities in Pakistan, to cater the production of tablets, capsules, syrups, suspensions, ointments and injectables. Maintaining Highest Quality Standards: In order to maintain quality stand
Slide 7: Manufacturing Capabilities
MANUFACTURING CAPABILITIES Ferozsons - Pharmaceutical Manufacturing Unit, Nowshera PEOPLE TRUST US
Slide 8: Clean Energy Initiatives
CLEAN ENERGY INITIATIVES To promote green energy and reduce carbon footprints, the Company installed two solar power plants of One-megawatt each. PEOPLE TRUST US
Slide 9: Corporate Social Responsibility
CORPORATE SOCIAL RESPONSIBILITY Company is committed to the protection of environment and investing in community’s health and education. During the year ended 30 June 2025, Company has contributed to various CSR activities including: Through collaboration Through this forum, MAGIC is pioneering init
Slide 10: Agenda
AGENDA 1. Company Profile 2 Collaborations & Product Portfolio 3 Pharmaceutical Industry Highlights 4 Financial Performance 5 Questions and Answers Session P PEOPLE TRUST US
Slide 11: Collaborations
COLLABORATIONS Grupo Empresarial 1 Bago S.A. 4 BioGaia Sweden 5 Nihon Kohden 2 Boston Scientific 3 Gilead Sciences PEOPLE TRUST US
Slide 12: Product Portfolio – Pharma
PRODUCT PORTFOLIO – PHARMA Our key therapeutic areas include: 1 Gastroenterology 2 Diabetes / Anti-Obesity 3 Cardiology 4 Hepatology 5 Urology 6 Pediatric 7 Antivirals / Infectious Diseases PEOPLE TRUST US
Slide 13: Product Portfolio – Medical Devices
PRODUCT PORTFOLIO – MEDICAL DEVICES Medical devices of following segments are marketed: 1 Cardiology 2 Endo 3 Urology 4 Electrophysiology 5 Cardiac Rhythm Management 6 Neuromodulation 7 Ultrasound / Other Diagnostic Machines PEOPLE TRUST US
Slide 14: New Brands in Our Portfolio
NEW BRANDS IN OUR PORTFOLIO PEOPLE TRUST US
Slide 15: Agenda
AGENDA 1. Company Profile 2 Collaborations & Product Portfolio 3 Pharmaceutical Industry Highlights 4 Financial Performance 5 Questions and Answers Session P PEOPLE TRUST US
Slide 16: Pharmaceutical Industry Highlights
PHARMACEUTICAL INDUSTRY HIGHLIGHTS 1 Market Size Overall Pakistan’s Retail Pharma Market stands at Rs. 1.12 Trillion. Growth and Growth over last year stands at 17.28%, whereas last 5 years CAGR 2 CAGR stands at 17.54%. 3 Approx. 97.3% market share is held by top 100 pharma corporates in Top Corpora
Slide 17: Agenda
AGENDA 1. Company Profile 2 Collaborations & Product Portfolio 3 Pharmaceutical Industry Highlights 4 Financial Performance 5 Questions and Answers Session P PEOPLE TRUST US
Slide 18: Financial Performance – Year Ended Jun 2025 (Standalone)
FINANCIAL PERFORMANCE – YEAR ENDED 30 JUN 2025 (STANDALONE) Revenue – net (Rs. in million) Overall topline of the Company grew by 9% over the last 15,000 Revenue year. Five-year CAGR is 20.88%. 14,500 14,000 13,858 13,500 Gross profit closed at Rs. 5,719 million, compared to Rs. 13,000 Gross 4,942 m
Slide 19: Financial Performance – Period Ended Sep 2025 (Standalone)
FINANCIAL PERFORMANCE – PERIOD ENDED 30 SEP 2025 (STANDALONE) Revenue – net Overall topline of the Company improve by 16% over the same (Rs. in million) Revenue period last year. 4,000 3,883 Gross profit closed at Rs. 1,580 million, compared to Rs. 1,307 3,357 Gross million in same period last year
Slide 20: Agenda
AGENDA 1. Company Profile 2 Collaborations & Product Portfolio 3 Pharmaceutical Industry Highlights 4 Financial Performance 5 Questions and Answers Session P PEOPLE TRUST US
Slide 21: Q&A Session
FEROZSONS 6H LABORATORIES LIMITED YEARS OF TRUST & DEVOTION Q&A SESSION F PEOPLE TRUST US
Slide 22: Thank You
THANK YOU
Ferozsons Laboratories — Investor Presentation (November 2025) on 6ix